Novel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the Literature

<div>(a) Hypercellular bone marrow core biopsy demonstrating interstitial proliferation of large lymphoma cells. Hematoxylin and eosin stained bone marrow core biopsy (×100). (b) CD30 immunohistochemical stain of the bone marrow core biopsy. A subset of the large lymphoma cells are CD30 positive. Ber-H2 antibody (×200).</div>

Case Reports in Oncological Medicine

fig2

Figure 2

Figure 2: Novel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the Literature 

Figure 2 | Novel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the Literature 